Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)
CATA
Cannabis as an Anti-cancer Agent: A Review of Medical Records in Patients With Cancer to Assess Potential Anti-cancer Benefits From Using Cannabis
1 other identifier
observational
50
1 country
1
Brief Summary
The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 19, 2021
CompletedFirst Submitted
Initial submission to the registry
July 25, 2025
CompletedFirst Posted
Study publicly available on registry
August 6, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2027
August 6, 2025
August 1, 2025
5.8 years
July 25, 2025
August 4, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To successfully complete Phase 2 by recruiting patients to consent with a simplified screening survey.
Successful completion of phase 2 of this survey study will include consenting 50 patients and obtaining their cancer and cannabis use details to validate anti-cancer claims.
From enrollment start to the obtainment of cancer diagnosis and treatment details and cannabis use history from each consented patient, which is estimated to take up to 6 years.
Eligibility Criteria
people with cancer who report that cannabis use had an impact on their cancer growth
You may qualify if:
- diagnosed with cancer
- have used any type of cannabis/marijuana, including those with cannabidiol (CBD) and/or tetrahydrocannabinol (THC) to treat their cancer
- believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker
You may not qualify if:
- does not have cancer
- has not used any type of cannabis/marijuana, including those with CBD and/or THC to treat their cancer
- does not believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
HealthPartners Institute Cancer Research Center
Saint Louis Park, Minnesota, 55426, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 25, 2025
First Posted
August 6, 2025
Study Start
March 19, 2021
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2027
Last Updated
August 6, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share